Lumigan (Bimatoprost) Patent Expiration, LOE Window & CMS Spending

Lumigan (Bimatoprost) by AbbVie: FDA Orange Book core substance LOE 2027-06-13, 2 AB generics, $665.4M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN022184 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2027-06-13
Last Listed Patent or Exclusivity Date2027-06-13
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$665.4M
2024 Medicare Part D Spend$647.2M
2024 Medicaid Spend$18.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.